Time for a strong recovery: 2015/05/22 0.00030 2015/05/15 0.00060 2015/05/12 0.0014
May 26, 2015: there were issued and outstanding 2,409,340,105 shares of the Common Stock
Waiting for news: In February of 2015, we entered into a non-binding letter of intent with EL for a proposed transaction, under which EL would pay us an up-front license fee of $1.75 million to secure a royalty stream from future sales of our Q Inside Safety Technology products to breast implant manufacturers other than EL. EL would also receive a 24 month option to purchase the technology and other assets related to the breast implant business for $10 million, less the amount of the up-front license fee.
Although the time period contemplated by the non-binding letter of intent has lapsed, we believe that EL continues to be interested in the proposed transaction and is continuing its efforts to close a predicate funding transaction in order to consummate the transaction with us. We will evaluate the desirability of doing so if and when EL re-presents the offer to us.
About VeriTeQ
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com. http://veriteqcorp.com/blog?category=Press Release
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.